Advertisement
Advertisement
PCSA
Processa Pharmaceuticals, Inc. Common
2.61
USDSponsored
+0.04
+1.56%
Aug 10, 15:59 UTC -4
Closed
After-Market
2.60
-0.01
-0.38%
PCSA Earnings Reports
Positive Surprise Ratio
PCSA beat 7 of 21 last estimates.
33%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.02
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-41.71%
Processa Pharmaceuticals, Inc. Common earnings per share and revenue
On Aug 05, 2026, PCSA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -1.02 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q3 26, 3 analysts forecast an EPS of -1.02 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Processa Pharmaceuticals, Inc. Common's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Processa Pharmaceuticals, Inc. Common reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Processa Pharmaceuticals, Inc. Common's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Processa Pharmaceuticals, Inc. Common expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Processa Pharmaceuticals, Inc. Common's next earnings report?
Based on 3
analysts, Processa Pharmaceuticals, Inc. Common is expected to report EPS of -$1.02 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement